CRISPR activation and interference as investigative tools in the cardiovascular system.

CRISPR-Cas Systems / genetics Transcriptional Activation Transcription Factors / genetics Cardiovascular System RNA, Guide, CRISPR-Cas Systems
CRISPR Cardiovascular DCas9 Transcriptional regulation

Journal

The international journal of biochemistry & cell biology
ISSN: 1878-5875
Titre abrégé: Int J Biochem Cell Biol
Pays: Netherlands
ID NLM: 9508482

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 05 07 2022
revised: 18 12 2022
accepted: 19 12 2022
pubmed: 24 12 2022
medline: 21 1 2023
entrez: 23 12 2022
Statut: ppublish

Résumé

CRISPR activation and interference (CRISPRa/i) technology offers the unprecedented possibility of achieving regulated gene expression both in vitro and in vivo. The DNA pairing specificity of a nuclease dead Cas9 (dCas9) is exploited to precisely target a transcriptional activator or repressor in proximity to a gene promoter. This permits both the study of phenotypes arising from gene modulation for investigative purposes, and the development of potential therapeutics. As with virtually all other organ systems, the cardiovascular system can deeply benefit from a broader utilisation of CRISPRa/i. However, application of this technology is still in its infancy. Significant areas for improvement include the identification of novel and more effective transcriptional regulators that can be docked to dCas9, and the development of more efficient methods for their delivery and expression in vivo.

Identifiants

DOI: 10.1016/j.biocel.2022.106348 PMID: 36563996 PMC: PMC10265131
pubmed: 36563996
pii: S1357-2725(22)00193-5
doi: 10.1016/j.biocel.2022.106348
pmc: PMC10265131
pii:
doi:

Substances chimiques

Transcription Factors 0
RNA, Guide, CRISPR-Cas Systems 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106348

Subventions

Organisme : British Heart Foundation
ID : RG/19/11/34633
Pays : United Kingdom

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Références

Nat Rev Cardiol. 2020 Apr;17(4):205-215
pubmed: 31582838
Nat Commun. 2018 Aug 29;9(1):3509
pubmed: 30158531
Nat Biotechnol. 2015 Nov;33(11):1159-61
pubmed: 26436575
Genome Res. 2018 Aug;28(8):1193-1206
pubmed: 29907613
PLoS One. 2012;7(5):e36754
pubmed: 22586493
Cell. 2013 Jul 18;154(2):442-51
pubmed: 23849981
Nat Med. 2018 Oct;24(10):1519-1525
pubmed: 30297904
Genome Biol. 2017 Sep 18;18(1):176
pubmed: 28923089
Nucleic Acids Res. 2016 Jun 20;44(11):5365-77
pubmed: 27198218
Nat Methods. 2018 Aug;15(8):611-616
pubmed: 30013045
Nat Methods. 2013 Oct;10(10):977-9
pubmed: 23892898
Nat Med. 2019 Mar;25(3):427-432
pubmed: 30778238
Nat Methods. 2013 Oct;10(10):973-6
pubmed: 23892895
Mol Ther. 2022 Jan 5;30(1):54-74
pubmed: 34678511
Nat Methods. 2015 Apr;12(4):326-8
pubmed: 25730490
Proc Natl Acad Sci U S A. 2007 Apr 24;104(17):7074-9
pubmed: 17438289
Nat Methods. 2015 Nov;12(11):1051-4
pubmed: 26344044
Methods Mol Biol. 2022;2573:53-61
pubmed: 36040586
Nature. 2015 Jan 29;517(7536):583-8
pubmed: 25494202
Nat Biotechnol. 2015 May;33(5):510-7
pubmed: 25849900
Cell Stem Cell. 2018 Feb 1;22(2):252-261.e4
pubmed: 29358044
Nat Methods. 2016 Jul;13(7):563-567
pubmed: 27214048
Mol Ther. 2020 Apr 8;28(4):1177-1189
pubmed: 31991108
Cell. 2016 Sep 22;167(1):233-247.e17
pubmed: 27662091
Nat Protoc. 2013 Nov;8(11):2180-96
pubmed: 24136345
Nat Methods. 2021 Aug;18(8):965-974
pubmed: 34341582
Nat Rev Cardiol. 2021 Jan;18(1):22-36
pubmed: 32895535
Rev Recent Clin Trials. 2006 May;1(2):169-82
pubmed: 18473969
Nat Biotechnol. 2016 Oct;34(10):1060-1065
pubmed: 27571369
Cell Stem Cell. 2016 Sep 1;19(3):406-14
pubmed: 27524438
Nat Neurosci. 2018 Mar;21(3):447-454
pubmed: 29403034
Mol Ther. 2020 Mar 4;28(3):723-746
pubmed: 31972133
ACS Chem Biol. 2018 Feb 16;13(2):406-416
pubmed: 29035510
Nat Methods. 2015 May;12(5):401-403
pubmed: 25775043
N Engl J Med. 2011 Apr 28;364(17):1643-56
pubmed: 21524215
J Thorac Cardiovasc Surg. 2022 Apr;163(4):1479-1490.e5
pubmed: 32682583
Methods Enzymol. 2014;546:161-74
pubmed: 25398340
J Clin Invest. 2008 Jan;118(1):124-32
pubmed: 18079970
Cell. 2014 Oct 23;159(3):635-46
pubmed: 25307933
Curr Opin Cardiol. 2018 May;33(3):298-303
pubmed: 29624510
Cell. 2013 Feb 28;152(5):1173-83
pubmed: 23452860
Acta Pharm Sin B. 2020 Feb;10(2):313-326
pubmed: 32082976
Nucleic Acids Res. 2017 Feb 28;45(4):1703-1713
pubmed: 27899645
Oncogene. 2002 Aug 12;21(35):5483-95
pubmed: 12154409
Elife. 2016 Sep 23;5:
pubmed: 27661255
Front Cardiovasc Med. 2018 Dec 06;5:175
pubmed: 30574507
Mol Ther. 2022 Jan 5;30(1):283-294
pubmed: 34298129
Science. 2012 Aug 17;337(6096):816-21
pubmed: 22745249
Circ Res. 2020 Jan 3;126(1):6-24
pubmed: 31730408
Science. 2019 Jan 18;363(6424):
pubmed: 30545847
J Biol Chem. 2005 Apr 8;280(14):13341-8
pubmed: 15671018
Mol Ther. 2016 Mar;24(3):508-21
pubmed: 26775808
Cell. 2014 Oct 23;159(3):647-61
pubmed: 25307932
Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16916-21
pubmed: 12481029
J Biol Chem. 2015 Oct 2;290(40):24367-80
pubmed: 26294766
Cell Syst. 2020 Jan 22;10(1):1-14
pubmed: 31972154
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Circ Res. 2014 May 23;114(11):1827-46
pubmed: 24855205
Hepatology. 2018 Aug;68(2):663-676
pubmed: 29091290
Oncotarget. 2016 Jul 19;7(29):46545-46556
pubmed: 27356740
Nat Med. 2019 Feb;25(2):249-254
pubmed: 30692695
Nat Commun. 2020 Aug 17;11(1):4132
pubmed: 32807781
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718
Cell. 2017 Dec 14;171(7):1495-1507.e15
pubmed: 29224783
Circ Res. 2017 Jan 6;120(1):39-48
pubmed: 27765793
Nat Neurosci. 2018 Mar;21(3):440-446
pubmed: 29335603

Auteurs

Melissa S Carroll (MS)

School of Cardiovascular and Metabolic Medicine & Sciences and British Heart Foundation Centre of Research Excellence, King's College London, London UK.

Mauro Giacca (M)

School of Cardiovascular and Metabolic Medicine & Sciences and British Heart Foundation Centre of Research Excellence, King's College London, London UK. Electronic address: mauro.giacca@kcl.ac.uk.

Articles similaires

Generation of isogenic models of Angelman syndrome and Prader-Willi syndrome in CRISPR/Cas9-engineered human embryonic stem cells.

Rachel B Gilmore, Dea Gorka, Christopher E Stoddard et al.
1.00
Prader-Willi Syndrome Humans Angelman Syndrome CRISPR-Cas Systems Human Embryonic Stem Cells

Expression interplay of genes coding for calcium-binding proteins and transcription factors during the osmotic phase provides insights on salt stress response mechanisms in bread wheat.

Diana Duarte-Delgado, Inci Vogt, Said Dadshani et al.
1.00
Triticum Transcription Factors Gene Expression Regulation, Plant Plant Proteins Salt Stress

Suppression of non-muscle myosin II boosts T cell cytotoxicity against tumors.

Yingyun Yang, Dahan Wen, Feng Lin et al.
1.00
Animals Humans Mice Neoplasms Tumor Microenvironment

Genome editing in Sub-Saharan Africa: a game-changing strategy for climate change mitigation and sustainable agriculture.

Peter Amoah, Abdoul-Razak Oumarou Mahamane, Moise Hubert Byiringiro et al.
1.00
Gene Editing Climate Change Africa South of the Sahara Crops, Agricultural Agriculture

Classifications MeSH

questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › Extinction de l'expression des gènes › Systèmes CRISPR-Cas › CRISPR activation and interference as...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Activation de la transcription › CRISPR activation and interference as...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › CRISPR activation and interference as...
questionsmedicales.fr › Système cardiovasculaire › CRISPR activation and interference as...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN non traduit › Petit ARN non traduit › Systèmes CRISPR-Cas, ARN, guide › CRISPR activation and interference as...